Displaying drugs 15101 - 15125 of 15236 in total
Betaine aldehyde
Experimental
3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol
Experimental
2,3-Dimethyl-1,4-naphthoquinone
Experimental
P-Hydroxybenzaldehyde
Experimental
1-Amino-1-Carbonyl Pentane
Experimental
Acetophenone
Experimental
REN-850
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
AP5346
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
PH94B
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE
Experimental
RAF-265
Investigational
8-azaxanthine
Experimental
3,5-Diaminophthalhydrazide
Experimental
ALGRX 1207
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
Nitrosoethane
Experimental
Napabucasin
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
Investigational
Pridopidine
Pridopidine has been used in trials studying the treatment of Huntington's Disease.
Investigational
Oxomemazine
Experimental
Displaying drugs 15101 - 15125 of 15236 in total